ACRS Valuation

Aclaris Therapeutics Inc

Add to Watchlist

Advanced Chart

1.930

+0.02(1.047%)1D

Overview
Forecast
Valuation
Earnings

ACRS Relative Valuation

ACRS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACRS is overvalued; if below, it's undervalued.

Historical Valuation

Aclaris Therapeutics Inc (ACRS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -6.49. The fair price of Aclaris Therapeutics Inc (ACRS) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 1.93 USD , Aclaris Therapeutics Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：1.93

Fair

Undervalued

-3.46

Trailing

Forward

0.00

EV/EBITDA

Aclaris Therapeutics Inc. (ACRS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.07. The thresholds are as follows: Strongly Undervalued below -6.59, Undervalued between -6.59 and -3.83, Fairly Valued between 1.70 and -3.83, Overvalued between 1.70 and 4.46, and Strongly Overvalued above 4.46. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.42

EV/EBIT

Aclaris Therapeutics Inc. (ACRS) has a current EV/EBIT of -0.42. The 5-year average EV/EBIT is -4.19. The thresholds are as follows: Strongly Undervalued below -14.44, Undervalued between -14.44 and -9.32, Fairly Valued between 0.93 and -9.32, Overvalued between 0.93 and 6.05, and Strongly Overvalued above 6.05. The current Forward EV/EBIT of -0.42 falls within the Historic Trend Line -Fairly Valued range.

31.52

Aclaris Therapeutics Inc. (ACRS) has a current PS of 31.52. The 5-year average PS is 72.13. The thresholds are as follows: Strongly Undervalued below -52.71, Undervalued between -52.71 and 9.71, Fairly Valued between 134.56 and 9.71, Overvalued between 134.56 and 196.98, and Strongly Overvalued above 196.98. The current Forward PS of 31.52 falls within the Historic Trend Line -Fairly Valued range.

-5.44

P/OCF

Aclaris Therapeutics Inc. (ACRS) has a current P/OCF of -5.44. The 5-year average P/OCF is -88.93. The thresholds are as follows: Strongly Undervalued below -677.11, Undervalued between -677.11 and -383.02, Fairly Valued between 205.17 and -383.02, Overvalued between 205.17 and 499.26, and Strongly Overvalued above 499.26. The current Forward P/OCF of -5.44 falls within the Historic Trend Line -Fairly Valued range.

-3.48

P/FCF

Aclaris Therapeutics Inc. (ACRS) has a current P/FCF of -3.48. The 5-year average P/FCF is -6.97. The thresholds are as follows: Strongly Undervalued below -17.52, Undervalued between -17.52 and -12.25, Fairly Valued between -1.70 and -12.25, Overvalued between -1.70 and 3.57, and Strongly Overvalued above 3.57. The current Forward P/FCF of -3.48 falls within the Historic Trend Line -Fairly Valued range.

Aclaris Therapeutics Inc (ACRS) has a current Price-to-Book (P/B) ratio of 1.59. Compared to its 3-year average P/B ratio of 2.03 , the current P/B ratio is approximately -21.86% higher. Relative to its 5-year average P/B ratio of 4.19, the current P/B ratio is about -62.14% higher. Aclaris Therapeutics Inc (ACRS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -36.40%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -25.44% , the current FCF yield is about -100.00% lower.

1.59

P/B

Median3y

2.03

Median5y

4.19

-4.86

FCF Yield

Median3y

-36.40

Median5y

-25.44

Competitors Valuation Multiple

The average P/S ratio for ACRS's competitors is 22.43, providing a benchmark for relative valuation. Aclaris Therapeutics Inc Corp (ACRS) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -35.76%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ACRS.O

Aclaris Therapeutics Inc

Theratechnologies Inc

Tiziana Life Sciences Ltd

Loss

202.86M

SGMT.O

Sagimet Biosciences Inc

Loss

282.92M

PRQR.O

ProQR Therapeutics NV

Performance Decomposition

Market capitalization of ACRS increased by 62.18% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -397.18 to -868.26.

The secondary factor is the P/E Change, contributed -20.67%to the performance.

Overall, the performance of ACRS in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-35.76%

2.77M → 1.78M

Revenue Growth

118.61%

-397.18 → -868.26

Margin Expansion

-20.67%

-1.86 → -1.47

P/E Change

62.18%